Vanqua Bio is helping usher in a new era of hope for the millions of people living with neurodegenerative diseases. Our unique drug-development approach is designed to overcome longstanding challenges in the neuroscience field by capitalizing on the power of human genetics to identify genes that cause or increase the risk of neurodegenerative disease. We leverage novel, proprietary research tools and in vitro modeling of disease, based on patient-derived neuronal cells, to develop transformative therapies that slow or stop the progression of Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Gaucher disease (GD).
Company Details
- Employees
- 33
- Founded
- -
- Address
- 2430 N Halsted Street,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.vanquabio.com/
- HQ
- Chicago, Illinois
Vanqua Bio Questions
Vanqua Bio's website is https://www.vanquabio.com/
Vanqua Bio's LinkedIn profile is https://www.linkedin.com/company/vanqua-bio
Vanqua Bio has
33 employees.
View email and phone details for 33
employees at Vanqua Bio.
Vanqua Bio's industry is
Biotechnology Research
Vanqua Bio's top competitors are
Exicure,
Evozyne,
Paragon Biosciences,
Maia Biotechnology, Inc.,
Emalex Biosciences,
Portal Innovations,
Circ Biosciences,
Dimension Bio,
Xeris Pharmaceuticals, Inc.,
Grove Biopharma, Inc..
Vanqua Bio's categories are Biotechnology Research
Vanqua Bio's founding year is 2019
